Osimertinib Treatment Was Unsuccessful for Lung Adenocarcinoma with G719S, S768I, and T790M Mutations

Epidermal growth factor receptor (EGFR) T790M mutations are the most frequent mechanism of resistance to first- and second-generation tyrosine kinase inhibitors, and osimertinib is an effective treatment for patients with both EGFR-activating mutations and T790M resistance mutations. We describe the...

Descripción completa

Detalles Bibliográficos
Autores principales: Nasu, Shingo, Shiroyama, Takayuki, Morita, Satomu, Takata, So, Takada, Hiromune, Masuhiro, Kentaro, Tanaka, Ayako, Morishita, Naoko, Suzuki, Hidekazu, Okamoto, Norio, Hirashima, Tomonori
Formato: Online Artículo Texto
Lenguaje:English
Publicado: The Japanese Society of Internal Medicine 2018
Materias:
Case Report
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6355418/
https://www.ncbi.nlm.nih.gov/pubmed/30146570
http://dx.doi.org/10.2169/internalmedicine.0923-18

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6355418/
https://www.ncbi.nlm.nih.gov/pubmed/30146570
http://dx.doi.org/10.2169/internalmedicine.0923-18

Ejemplares similares